Tag: Parkinson’s
Multiple Penicillin Courses Linked to Modestly Lower Risk for Parkinson Disease
Increase in PD risk seen in association with exposure to two or more courses of antifungals one to five years prior
FDA Approves Vyalev for Advanced Parkinson Disease
Vyalev is the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy for treatment of motor fluctuations
Air Pollution Exposure Increases Risk for Parkinson Disease
Among those with Parkinson disease, air pollution tied to higher risk for developing akinetic rigid disease and dyskinesia
SGLT2i Use Linked to Lower Risk for Neurodegenerative Disease in T2DM
Reduced risk for Alzheimer disease, vascular dementia, and Parkinson disease seen with SGLT2i use in type 2 diabetes
Upper GI Mucosal Damage Tied to Later Parkinson Disease Diagnosis
Authors say increased vigilance is warranted for patients with mucosal damage
Migraine in Women Not Linked to Risk for Parkinson Disease
No associations seen for migraine with aura, migraine without aura, history of migraine in cohort of middle-aged women
Dementia May Occur Less Often, Develop Slower in Parkinson Disease Patients
Median time to dementia was 15 years in Penn cohort; estimated probability of dementia at year 10 was 9 to 15 percent in PPMI cohort
Fecal Microbiota Transplant No Aid for Parkinson Disease
At six months, no significant changes seen in Movement Disorder Society Unified Parkinson’s Disease Rating Scale scores versus placebo
Risk of Parkinson Disease Heightened in People With Anxiety
Certain clinical features may identify those who may be in prodromal phase of Parkinson disease
Parkinsonism Occurs Frequently in Chronic Traumatic Encephalopathy
More severe CTE stage and nigral pathology seen for participants with parkinsonism versus those without parkinsonism
